Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Monika Szarejko"'
Autor:
Paulina Kwaśnik, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogląd, Bogdan Ochrem, Grażyna Bober, Ewa Wasilewska, Iwona Hus, Monika Szarejko, Witold Prejzner, Olga Grzybowska-Izydorczyk, Agnieszka Klonowska-Szymczyk, Ewa Mędraś, Michał Kiełbus, Tomasz Sacha, Krzysztof Giannopoulos
Publikováno v:
Cells, Vol 13, Iss 8, p 723 (2024)
Treatment-free remission (TFR) is achieved in approximately half of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The mechanisms responsible for TFR maintenance remain elusive. This study aimed to identify immune ma
Externí odkaz:
https://doaj.org/article/c7e72887b430405ca12d1be455f84335
Autor:
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of the
Externí odkaz:
https://doaj.org/article/0bf9f72785bc4d0cad26c30e6349239e
Autor:
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Alice FABARIUS, Hana Klamova, B Spieß, Cornelius Waller, Tim Bruemmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Satu Mustjoki, Edgar Faber, Jiri Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Janusz Kloczko, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois-Xavier Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that refl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6488731f910555df7d7fa196a4610f36
https://doi.org/10.21203/rs.3.rs-2770615/v1
https://doi.org/10.21203/rs.3.rs-2770615/v1
Autor:
Marek Dudziński, Justyna Gil, Iwona Pietkun, Krzysztof Giannopoulos, Joanna Niesiobedzka-Krezel, Joanna Góra-Tybor, Grażyna Bober, Ewa Wasilewska, Ewa Mędraś, Jadwiga Hołojda, Tomasz Sacha, Monika Szarejko, Olga Grzybowska-Izydorczyk, Krzysztof Myśliwiec, Joanna Wącław, Michał Gniot
Publikováno v:
American Journal of Hematology. 92:E125-E128
The efficacy and safety of imatinib generics were not studied and reported on larger cohort of patients yet. We report on efficacy and safety of imatinib generics in 726 chronic myeloid leukemia patients in chronic phase who completed one-year observ
Autor:
Monika Szarejko, Stefan Knop, Jan Dürig, Bansod Sudhir, Guy Lemaillet, Elena Rivolti, Hartmut Goldschmidt, Mattia D'Agostino, Barbara Gamberi, Artur Jurczyszyn, Sara Bringhen, Doris Lang, Angelo Vacca, Roberto Ria, Jorge Castellano Acosta, Norbert Grząśko, Marc S. Raab
Background Bone marrow neovascularization is a hallmark of multiple myeloma and progression is associated with a substantial increase in pro-angiogenic factors that promote bone marrow angiogenesis, including vascular endothelial growth factor (VEGF-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc70a0a6254da54d0425d6e4072934c8
Autor:
Marc S. Raab, Bansod Sudhir, Monika Szarejko, Jorge Castellano Acosta, Angelo Vacca, Sara Bringhen, Stefan Knop, Artur Jurczyszyn, Barbara Gamberi, Norbert Grząśko, Cedric Cortijo, Jan Dürig, Guy Lemaillet, Hartmut Goldschmidt
Publikováno v:
Blood. 132:1980-1980
Background MP0250 is a first-in-class selective tri-specific multi-DARPin® drug candidate neutralizing VEGF-Α and HGF as well as binding to human serum albumin to increase its plasma half-life. Preclinical studies have shown that MP0250 enhances se
Autor:
Ewa Wasilewska, Krzysztof Giannopoulos, Michał Gniot, Tomasz Sacha, Iwona Pietkun, Krzysztof Myśliwiec, Joanna Góra-Tybor, Joanna Niesiobedzka-Krezel, Grażyna Bober, Joanna Wącław, Olga Grzybowska-Izydorczyk, Marek Dudziński, Justyna Gil, Ewa Mędraś, Monika Szarejko
Publikováno v:
Blood. 128:629-629
Background: Generic imatinib is already available in several countries. The use of generic imatinib is expected to lower the cost of CML therapy, however the data regarding their efficacy and tolerability in larger populations of CML patients are lac
Autor:
Beata Piatkowska-Jakubas, Jerzy Holowiecki, Barbara Zdziarska, Anna Dmoszynska, Krystyna Zawilska, Monika Szarejko, Janusz Kloczko, Sebastian Giebel, Jolanta Starzak-Gwozdz, Andrzej Hellmann, Ewa Lech-Marańda, Aleksander B. Skotnicki, Maria Domagala, Anna Czyż, Malgorzata Krawczyk-Kulis, Tadeusz Robak, Krzysztof Warzocha, Anna Ejduk, Kazimierz Sulek, Wiesław Wiktor Jędrzejczak, Slawomira Kyrcz-Krzemien, Malgorzata Razny, Monika Paluszewska, Krystyna Jagoda, Maria Adamczyk-Cioch, Mieczysław Komarnicki, Jaroslaw Piszcz, Beata Stella-Holowiecka
Publikováno v:
Publons
Abstract 2138 In a previous study by the Polish Adult Leukemia Group (PALG 4–2002) we demonstrated that status of minimal residual disease (MRD) during induction-consolidation is the most important factor predicting long-term outcome of adult ALL (
Publikováno v:
ResearcherID
Thrombotic thrombocytopenic purpura (TTP) is a rare dynamic life-threatening disease with systemic formation of platelet thrombi in the microvasculature within all the organs. Until recently the mortality in TTP has exceeded 90%. The progress of medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942040aff1674068ecff6fb3d15823e1
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=MEDLINE&KeyUT=MEDLINE:18018386&KeyUID=MEDLINE:18018386
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=MEDLINE&KeyUT=MEDLINE:18018386&KeyUID=MEDLINE:18018386